[New aspects of the action and use of antireticular cytotoxic serum].
D000818:Animals; D015478:Antigens, Heterophile / Q000302:isolation & purification*; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy; D002784:Cholesterol / Q000097:blood; D003095:Collagen Diseases / Q000188:drug therapy; D003238:Connective Tissue / Q000187:drug effects / Q000276:immunology; D006168:Guinea Pigs; D006736:Horses / Q000276:immunology; D006801:Humans; D006969:Hypersensitivity, Immediate; D007106:Immune Sera / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D007116:Immunization, Passive; D050356:Lipid Metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy; D011506:Proteins / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D014945:Wound Healing / Q000187:drug effects
D015478:Antigens, Heterophile; D007106:Immune Sera; D011506:Proteins; D002784:Cholesterol
Novye aspekty deĭstviia i primeneniia antiretikuliarnoĭ tsitotoksicheskoĭ syvorotki